< Back to previous page

Project

Deregulated signaling pathways in cancer: from genetic insights towards targeted therapy.

Normal.dotm 0 0 1 201 1147 K.U.Leuven - VIB 9 2 1408 12.0 0 false 18 pt 18 pt 0 0 false false false /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman"; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} Cancer development is a stepwise process, which involves the deregulation of several signaling pathways implicated in cell proliferation, differentiation, programmed cell death and survival, migration, self renewal, etc. While many cancer specific mutations are known, new technologies are expected to identify still a variety of novel aberrations as well as new targets for therapy. Over the past 30 years, many different genomic rearrangements and mutations have been discovered in cancer. The speed at which these discoveries occur has steadily increased, mainly owing to technological improvements such as genome-wide array analyses and more recently next-generation sequencing. In addition, RNAi technology has opened up new possibilities for functional studies in cancer cells, and has provided a unique tool to identify essential genes/proteins for cancer cell proliferation, migration, and survival. In this project we want to integrate molecular, functional and chemical compound screens to identify novel molecular defects and critical signaling pathways in solid tumors and hematological malignancies. This work aims to generate novel insights in the fundamental aspects of cancer development and to use this information to identify novel targets for therapy. In combination with chemical compound screens, this project may provide lead compounds for further drug development.
Date:1 Oct 2010 →  30 Nov 2016
Keywords:tumor suppressor genes, drug screens, signaling, molecular genetics, oncogenes, cancer, cell survival, cell proliferation, RNAi screens